Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of atogepant for prevention of menstrual migraine
jRCT2051240268Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of atogepant in Catamenial Migraine (3 arms), sponsored by AbbVie Inc. Started Apr 2025; status: active, not recruiting.
02
Drugs
atogepant
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on jRCT2051240268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240268.